Yahoo · Oct 24, 2026
Cencora's Q4 2026 Earnings: What to Expect
Cencora is scheduled to release its fourth-quarter results next month, with analysts projecting double-digit earnings growth.
NYSE · COR
Cencora, Inc.
Healthcare · Medical - Distribution
$330.53
Up+$0.31 (+0.09%)
Updated Oct 30, 2026, 11:51 PM
SID Score
5.6/10
Composite research score
Smart Money
47/100
Neutral
- Market cap
- 66.71B
- P/E ratio
- 42.94
- Dividend yield
- 0.68%
- 52-week range
- $244.82 – $376.92
- Volume
- 1.03M
- Avg. volume
- 1.54M
Price performance · COR
COR price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
COR closed at $330.53 after 21 trading sessions, up 6.70% for the selected period.
- Last close
- $330.53
- Period change
- +6.70%
- Period low
- $309.05
- Period high
- $343.27
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $328.84 | $331.07 | $326.335 | $330.53 | 1.03M |
| Oct 28, 2026 | $321.82 | $327.43 | $320.06 | $324.35 | 1.08M |
| Oct 27, 2026 | $327.77 | $330.15 | $325.00 | $325.37 | 1.12M |
| Oct 26, 2026 | $331.60 | $335.45 | $329.1701 | $330.00 | 993.48K |
| Oct 23, 2026 | $337.15 | $338.07 | $330.31 | $331.00 | 1.17M |
| Oct 22, 2026 | $344.43 | $344.43 | $337.11 | $338.48 | 1.18M |
| Oct 21, 2026 | $343.05 | $344.44 | $338.34 | $340.43 | 1.51M |
| Oct 20, 2026 | $343.50 | $345.00 | $339.53 | $343.27 | 916.88K |
| Oct 19, 2026 | $338.13 | $342.18 | $336.47 | $340.00 | 1.03M |
| Oct 16, 2026 | $343.31 | $343.31 | $339.01 | $340.92 | 1.98M |
| Oct 15, 2026 | $342.70 | $345.46 | $339.26 | $341.41 | 1.59M |
| Oct 14, 2026 | $332.08 | $336.33 | $330.82 | $336.17 | 1.19M |
| Oct 13, 2026 | $328.07 | $331.60 | $327.105 | $330.11 | 1.11M |
| Oct 12, 2026 | $325.37 | $327.9599 | $323.64 | $325.06 | 959.16K |
| Oct 9, 2026 | $319.50 | $325.82 | $318.79 | $323.85 | 781.95K |
| Oct 8, 2026 | $316.59 | $322.58 | $314.90 | $321.35 | 897.58K |
| Oct 7, 2026 | $317.30 | $322.41 | $315.15 | $317.25 | 1.06M |
| Oct 6, 2026 | $314.63 | $316.44 | $311.83 | $316.37 | 817.91K |
| Oct 5, 2026 | $309.43 | $316.06 | $307.87 | $314.93 | 1.15M |
| Oct 2, 2026 | $308.29 | $310.425 | $302.14 | $309.05 | 1.16M |
| Oct 1, 2026 | $303.18 | $313.02 | $300.77 | $309.78 | 1.89M |
Latest COR news
The latest Smart Investors Daily articles mentioning COR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
COR research
Overview
Company profile and research snapshot.
Company profile
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $373.17
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 22, 2026 | Baird | Outperform | — |
| Oct 20, 2026 | Argus Research | Buy | — |
| Oct 16, 2026 | UBS | Buy | — |
| Oct 7, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | RBC Capital | Sector Perform | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 22, 2026
Baird Maintains Outperform on Cencora, Raises Price Target to $375
Baird analyst David Rodgers maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $373 to $375.
Benzinga · Oct 21, 2026
Here’s How Much You Would Have Made Owning Cencora Stock In The Last 5 Years
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 11.54% on an annualized basis producing an average annual return of 22.6%. Currently, Cencora has a market capitalization of $64.88 billion.
Yahoo · Oct 20, 2026
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Amgen boasts stronger revenue growth, while Bristol Myers Squibb generates nearly 60% more free cash flow at half the valuation.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
